Mesa Laboratories, Inc. $MLAB Shares Bought by Diamond Hill Capital Management Inc.

Diamond Hill Capital Management Inc. grew its holdings in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 218.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 123,381 shares of the medical instruments supplier’s stock after purchasing an additional 84,582 shares during the quarter. Diamond Hill Capital Management Inc. owned approximately 2.24% of Mesa Laboratories worth $8,268,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Mesa Laboratories in the second quarter worth approximately $452,000. Geneva Capital Management LLC raised its stake in Mesa Laboratories by 5.2% during the second quarter. Geneva Capital Management LLC now owns 199,092 shares of the medical instruments supplier’s stock worth $18,758,000 after purchasing an additional 9,780 shares during the period. AlphaQuest LLC boosted its holdings in shares of Mesa Laboratories by 9,667.7% in the 2nd quarter. AlphaQuest LLC now owns 6,056 shares of the medical instruments supplier’s stock valued at $571,000 after purchasing an additional 5,994 shares during the last quarter. Boston Partners grew its stake in shares of Mesa Laboratories by 16.3% during the 2nd quarter. Boston Partners now owns 5,421 shares of the medical instruments supplier’s stock valued at $511,000 after buying an additional 758 shares during the period. Finally, MQS Management LLC purchased a new stake in shares of Mesa Laboratories during the 2nd quarter valued at $207,000. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Mesa Laboratories in a research report on Thursday, January 22nd. Wells Fargo & Company raised their price objective on Mesa Laboratories from $83.00 to $94.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. Zacks Research upgraded Mesa Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. Finally, Wall Street Zen upgraded shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $94.00.

Mesa Laboratories Stock Performance

Shares of MLAB stock opened at $93.27 on Monday. Mesa Laboratories, Inc. has a 12-month low of $55.45 and a 12-month high of $155.12. The firm has a market capitalization of $514.85 million, a price-to-earnings ratio of 145.74 and a beta of 0.89. The business has a 50 day simple moving average of $82.11 and a 200 day simple moving average of $74.93. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.94 and a quick ratio of 1.45.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings data on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.66. The business had revenue of $65.13 million for the quarter, compared to analysts’ expectations of $63.23 million. Mesa Laboratories had a net margin of 1.51% and a return on equity of 22.02%. On average, equities research analysts anticipate that Mesa Laboratories, Inc. will post 8 EPS for the current year.

Mesa Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Saturday, February 28th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.64 annualized dividend and a yield of 0.7%. Mesa Laboratories’s dividend payout ratio (DPR) is currently 100.00%.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.